SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 20, 2004

 

ORPHAN MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-24760

 

41-1784594

(State or other jurisdiction
of incorporation)

 

(Commission file number)

 

(I.R.S. employer identification number)

 

Suite 250,
13911 Ridgedale Drive,
Minnetonka, MN

 

55305

 

(952) 513-6900

(Address of principal executive
offices)

 

(zip code)

 

(Registrant’s telephone number,
including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On October 20, 2004, Orphan Medical issued a press release discussing third quarter 2004 results. The press release is included as Exhibit 99.1 hereto and is incorporated herein by reference. The press release contains forward-looking statements regarding the Company and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.

 

Item 9.01.  Financial Statements and Exhibits

 

(c)           Exhibits

 

99.1         Press release dated October 20, 2004

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 22, 2004

ORPHAN MEDICAL, INC.

 

 

 

 

 

 

 

 

/s/ Timothy G. McGrath

 

 

 

Timothy G. McGrath

 

 

Chief Financial Officer

 

 

(duly authorized officer and
principal financial officer)

 

3


 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press release dated October 20, 2004.

 

4